Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice

Biologicals

Volumn 40, Issue 2, 2012, Pages 140-145

  Al Mariri, Ayman ^a   Mahmoud, Nermeen Haj ^a   Hammoud, Razan ^a  

^a DEPARTMENT OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Syrian Arab Republic)

Author keywords

Adjuvant; Brucella; E. coli; Oligodeoxynucleotides; Protection

Indexed keywords

BACTERIAL VACCINE; CPG OLIGODEOXYNUCLEOTIDE VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PROTEIN P39; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BRUCELLA MELITENSIS; BRUCELLOSIS; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GENETIC CODE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOBLOTTING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; P39 GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BRUCELLA MELITENSIS; BRUCELLA VACCINE; BRUCELLOSIS; CPG ISLANDS; ESCHERICHIA COLI; FEMALE; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PERIPLASMIC BINDING PROTEINS; RECOMBINANT PROTEINS; TIME FACTORS;

ANIMALIA; BRUCELLA; BRUCELLA MELITENSIS; BRUCELLA MELITENSIS 16M; ESCHERICHIA COLI; MUS; NEGIBACTERIA;

EID: 84858080968     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.01.002     Document Type: Article

References (31)

1. Meng X.J., Lindsay D.S., Sriranganathan N. Wild boars as sources for infectious diseases in livestock and humans. Philos Trans R Soc Lond B Biol Sci 2009, 27:2697-2707.
2. Whatmore A.M. Current understanding of the genetic diversity of Brucella, an expanding genus of zoonotic pathogens. Infect Genet Evol 2009, 9:1168-1184.
3. Godfroid J., Nielsen K., Saegerman C. Diagnosis of brucellosis in livestock and wildlife. Croat Med J 2010, 51:296-305.
4. DelVecchio V.G., Alefantis T., Ugalde R.A., Comerci D., Marchesini M.I., Khan A., et al. Identification of protein candidates for developing bacterial ghost vaccines against Brucella. Methods Biochem Anal 2006, 49:363-377.
5. Olsen S.C., Stoffregen W.S. Essential role of vaccines in brucellosis control and eradication programs for livestock. Expert Rev Vaccines 2005, 4:915-928.
6. Glynn M.K., Lynn T.V. Brucellosis. J Am Vet Med Assoc 2008, 15:900-908.
7. Boschiroli M.L., Foulongne V., O'Callaghan D. Brucellosis: a worldwide zoonosis. Curr Opin Microbiol 2001, 4:58-64.
8. Golding B., Scott D.E., Scharf O., Huang L., Zaitseva M., Lapham C.N., et al. Immunity and protection against Brucella abortus. Microbes Infect 2001, 3:43-48.
9. Denoel P.A., Vo T.K., Weynants V.E., Tibor A., Gilson D., Zygmunt M.S., et al. Identification of the major T-cell antigens present in the Brucella melitensis B115 protein preparation, Brucellergene OCB. J Med Microbiol 1997, 46:801-806.
10. Ilvesaro J.M., Merrell M.A., Li L., Wakchoure S., Graves D., Brooks S., et al. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 2008, 6:1534-1543.
11. Gupta K., Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 2008, 9:137-145.
12. McCluskie M.J., Krieg A.M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 2006, 311:155-178.
13. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006, 25:135-154.
14. Baldwin C.L., Parent M. Fundamentals of host immune response against Brucella abortus: what the mouse model has revealed about control of infection. Vet Microbiol 2002, 90:367-382.
15. Al-Mariri A. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherichia coli expression Brucella P39 protein. Vaccine 2010, 17:1766-1770.
16. Pasquevich K.A., Ibañez A.E., Coria L.M., García Samartino C., Estein S.M., Zwerdling A., et al. An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice. PLoS One 2011, 14(6):e16203.
17. Zhao Z., Li M., Luo D., Xing L., Wu S., Duan Y., et al. Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. Vaccine 2009, 20:5214-5219.
18. Rajasekaran P., Surendran N., Seleem M.N., Sriranganathan N., Schurig G.G., Boyle S.M. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge. Vaccine 2011, 12:3106-3110.
19. Al-Mariri A., Tibor A., Mertens P., DeBolle X., Michel P., Godefroid J., et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 2001, 69:4816-4822.
20. Oliveira S.C., Splitter G.A. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 1996, 14:959-962.
21. Onate A.A., Vemulapalli R., Andrews E., Schurig G.G., Boyle S., Folch H. Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus. Infect Immun 1999, 67:986-988.
22. Dietrich G., Bubert A., Gentschev I., Sokolovic Z., Simm A., Catic A., et al. Delivery of antigenencoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol 1998, 16:181-185.
23. Langermann S., Palaszynski S.R., Burlein J.E., Koenig S., Hanson M.S., Briles D.E., et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant Bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J Exp Med 1994, 180:2277-2286.
24. Curtiss R., Hassan J.O. Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Vet Immunol Immunopathol 1996, 54:365-372.
25. Vemulapalli R., He Y., Boyle S.M., Sriranganathan N., Schurig G.G. Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses. Infect Immun 2000, 68:3290-3296.
26. Guilloteau L.A., Laroucau K., Vizcaino N., Jacques I., Dubray G. Immunogenicity of recombinant Escherichia coli expressing the omp31 gene of Brucella melitensis in BALB/c mice. Vaccine 1999, 1999(17):353-361.
27. Al-Mariri A., Tibor A., Lestrate P., Mertens P., DeBolle X., Letesson J.J. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus Bacterioferritin or P39 antigen. Infect Immun 2002, 70:1915-1923.
28. Pichichero M.E. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008, 4:262-270.
29. Klinman D.M. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 2004, 4:937-946.
30. Tross D., Klinman D.M. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J Immunol 2008, 181:5785-5790.
31. Kaushik P., Singh D.K., Kumar S.V., Tiwari A.K., Shukla G., Dayal S., et al. Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides 2010, 34:119-132.